Cargando…

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States

INTRODUCTION/AIMS: Data regarding weight, height/length, and growth status of patients with spinal muscular atrophy (SMA) who have received only supportive care are limited. This cross‐sectional study describes these measurements in patients with Type 1 and Types 2/3 SMA and compares them with refer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darras, Basil T., Guye, Sabrina, Hoffart, Janine, Schneider, Sophie, Gravestock, Isaac, Gorni, Ksenija, Fuerst‐Recktenwald, Sabine, Scalco, Renata S., Finkel, Richard S., De Vivo, Darryl C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Research Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325433/ https://www.ncbi.nlm.nih.gov/pubmed/35385150 http://dx.doi.org/10.1002/mus.27556

Ejemplares similares

Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
por: Cances, Claude, et al.
Publicado: (2022)

Ethical Perspectives on Treatment Options with Spinal Muscular Atrophy Patients
por: Yeo, Crystal J. J., et al.
Publicado: (2022)

Disease Burden of Spinal Muscular Atrophy: A Comparative Cohort Study Using Insurance Claims Data in the USA
por: Mouchet, Julie, et al.
Publicado: (2023)

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
por: Sergott, Robert C., et al.
Publicado: (2020)

Longitudinal natural history of type I spinal muscular atrophy: a critical review
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Yeo and Darras: Extraneuronal Phenotypes of Spinal Muscular Atrophy
por: Yeo, Crystal Jing Jing, et al.
Publicado: (2020)

Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy
por: Chiriboga, Claudia A., et al.
Publicado: (2016)

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy
por: Kobayashi, Dione T., et al.
Publicado: (2013)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
por: Lo, Siu Hing, et al.
Publicado: (2021)

Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

Spinal muscular atrophy, pediatric virology and gene therapy: A challenge of modern weakness and hope
por: Darras, Basil T., et al.
Publicado: (2018)

Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Dysphagia Phenotypes in Spinal Muscular Atrophy: The Past, Present, and Promise for the Future
por: McGrattan, Katlyn Elizabeth, et al.
Publicado: (2021)

Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures
por: Aponte Ribero, Valerie, et al.
Publicado: (2023)

Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
por: Ramsey, Danielle, et al.
Publicado: (2017)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Systemic nature of spinal muscular atrophy revealed by studying insurance claims
por: Lipnick, Scott L., et al.
Publicado: (2019)

Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
por: Glascock, Jacqueline, et al.
Publicado: (2018)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Different trajectories in upper limb and gross motor function in spinal muscular atrophy
por: Coratti, Giorgia, et al.
Publicado: (2021)

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study
por: Trucco, Federica, et al.
Publicado: (2021)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results
por: Finkel, Richard S., et al.
Publicado: (2023)

Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities
por: Rodriguez-Torres, Rafael S., et al.
Publicado: (2023)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_49ecdnm66mn8gu6akldcv0kkt9